Dr. Vincent Fradet (MD, PhD, FRCSC) is an uro-oncologist with a focused clinical practice at CHU de Québec-Laval University. He completed his medical training at Université de Montréal with an MD and residency in urology. He pursued with 5 years of subspecialty and research training. He obtained his uro-oncology accreditation from the Society of Urologic Oncology at the University of California, in San Francisco (UCSF) and completed a PhD in Clinical Research/Epidemiolgy (University de Montréal). Dr. Fradet has been an Associate Professor at Laval University since 2009, and is a regular researcher at the Laval University Cancer Research Center and at INAF (Institute for Nutrition and functional Food).

Dr. Fradet’s research goal is to improve our understanding of the links between lifestyle factors, including dietary omega-3 fatty acids and exercise, quality of life parameters, inflammation, and oncogenic pathways in prostate cancer, to progressively develop personalized preventive and treatment strategies. To that end, Dr. Fradet has built a unique biobank of bio-samples, developed pre-clinical models (mouse and primary cells in culture) and is running some clinical studies. All the epidemiological, clinical, and molecular (translational) projects led by his team are focused on improving our understanding of the biological mechanisms and the impact on quality of life of prostate cancer, as well as on developing biomarkers (urinary, blood, epigenetics, molecular and/or cellular) to be used in future intervention studies to stratify or select and monitor patients.

Hôpital de l'Enfant-Jésus
1401, 18e rue
G4.610
Québec, QC
Canada G1J 1Z4
+1 418-525-4444, extension 67694
Vincent.Fradet@crchudeque... vincent.fradet@fmed.ulava...

Latest news

66 entries « ‹ 1 of 7 › »

Molina OE, LaRue H, Simonyan D, Hovington H, Têtu B, Fradet V, Lacombe L, Toren P, Bergeron A, Fradet Y

High infiltration of CD209+ dendritic cells and CD163+ macrophages in the peritumor area of prostate cancer is predictive of late adverse outcomes

Journal Article

Front Immunol, 14 , 2023.

Abstract | Links:

Moussa H, Robitaille K, Pelletier JF, Tourigny R, Fradet Y, Lacombe L, Toren P, Lodde M, Tiguert R, Dujardin T, Caumartin Y, Duchesne T, Julien P, Savard J, Diorio C, Fradet V

Effects of Concentrated Long-Chain Omega-3 Polyunsaturated Fatty Acid Supplementation on Quality of Life after Radical Prostatectomy: A Phase II Randomized Placebo-Controlled Trial (RCT-EPA)

Journal Article

Nutrients, 15 (6), 2023.

Abstract | Links:

Klimis H, Pinthus JH, Aghel N, Duceppe E, Fradet V, Brown I, Siemens DR, Shayegan B, Klotz L, Luke PP, Niazi T, Lavallee LT, Mousavi N, Hamilton RJ, Chin JL, Gopaul D, Violette PD, Davis MK, Hanna N, Sabbagh R, Ben Zadok OI, Hajjar LA, Kann AG, Mian R, Rangarajan S, Huei Ng KK, Iakobishvili Z, Selvanayagam JB, Avezum A, Leong DP

The Burden of Uncontrolled Cardiovascular Risk Factors in Men With Prostate Cancer: A RADICAL-PC Analysis

Journal Article

JACC CardioOncol, 5 (1), 2023.

Abstract | Links:

Fadel J, Simonyan D, Fradet V, Lodde M, Lacombe L, Fradet Y, Toren P

Analysis of sex-based differences to Bacillus Calmette-Guérin for non-muscle invasive bladder cancer

Journal Article

Urol Oncol, 40 (12), 2022.

Abstract | Links:

Fradet S, Pelletier JF, Singbo N, Lacombe L, Toren P, Lodde M, Dujardin T, Tiguert R, Fradet Y, Robitaille K, Fradet V

Effects of omega-3 fatty acids supplementation on perioperative blood loss and complications after radical prostatectomy

Journal Article

Clin Nutr ESPEN, 47 , 2022.

Abstract | Links:

Boibessot C, Molina O, Lachance G, Tav C, Champagne A, Neveu B, Pelletier JF, Pouliot F, Fradet V, Bilodeau S, Fradet Y, Bergeron A, Toren P

Subversion of infiltrating prostate macrophages to a mixed immunosuppressive tumor-associated macrophage phenotype

Journal Article

Clin Transl Med, 12 (1), 2022.

Abstract | Links:

Pinthus JH, Duivenvoorden WCM, Klotz L, Mukherjee SD, Siemens DR, Niazi T, Fradet V, Foster W, Duceppe E, Taussky D, Hamilton R, Lavallée L, Brown I, Chin J, Gopaul D, Wassef A, Kassouf W, Davis M, Violette PD, Agapay S, Balasubramanian K, Mian R, Rangarajan S, Sener A, Shayegan B, Devereaux PJ, Leong DP

Low Serum Testosterone in Men with Newly Diagnosed Androgen-Deprivation Therapy-Naïve Prostate Cancer and Its Relationship to Cardiovascular Risk Factors: A RADICAL-PC Substudy

Journal Article

J Urol, 207 (5), 2022.

Abstract | Links:

Pavlovich CP, Hyndman ME, Eure G, Ghai S, Caumartin Y, Herget E, Young JD, Wiseman D, Caughlin C, Gray R, Wason S, Mettee L, Lodde M, Toi A, Dujardin T, Lance R, Schatz SM, Fabrizio M, Malcolm JB, Fradet V

A multi-institutional randomized controlled trial comparing first-generation transrectal high-resolution micro-ultrasound with conventional frequency transrectal ultrasound for prostate biopsy

Journal Article

BJUI Compass, 2 (2), 2021.

Abstract | Links:

Cléophat JE, Dorval M, El Haffaf Z, Chiquette J, Collins S, Malo B, Fradet V, Joly Y, Nabi H

Whether, when, how, and how much? General public's and cancer patients' views about the disclosure of genomic secondary findings

Journal Article

BMC Med Genomics, 14 (1), 2021.

Abstract | Links:

Savija N, Leong DP, Pinthus J, Karampatos S, Shayegan B, Mian R, Rangarajan S, Fradet V, de Souza RJ, Mente A, Dehghan M

Development and Comparability of a Short Food-Frequency Questionnaire to Assess Diet in Prostate Cancer Patients: The Role of Androgen Deprivation Therapy in CArdiovascular Disease - A Longitudinal Prostate Cancer Study (RADICAL PC) Substudy

Journal Article

Curr Dev Nutr, 5 (11), 2021.

Abstract | Links:

66 entries « ‹ 1 of 7 › »
Signaler des ajouts ou des modifications

Active projects

  • Bactériophages et immunothérapie en cancer de la prostate, from 2023-05-03 to 2024-03-31
  • En route towards prebiotic clinical trials for enhancement of immunotherapies in bladder and prostate cancers, from 2020-06-01 to 2024-04-30
  • Habitudes de vie, biomarqueurs et risque de cancer de la prostate, from 2022-04-01 to 2024-03-31
  • Institut sur la nutrition et les aliments fonctionnels (INAF), from 2017-04-01 to 2024-03-31
  • Les habitudes de vie en cancer de la prostate au coeur d’une médecine personnalisée, from 2021-07-01 to 2024-06-30
  • Repurposing bicalutamide to improve the response to immune checkpoint inhibition for treatment of advanced urothelial carcinoma, from 2022-08-01 to 2026-07-31
  • Rôle des habitudes de vie sur le microbiote et la réponse clinique à l’immunothérapie en cancer de la vessie, from 2023-04-20 to 2024-03-31
  • What are my options? A feasibility study of a personalized primary prevention strategy for women and men at high risk of breast and prostate cancer, from 2022-01-15 to 2024-01-14

Recently finished projects

  • Impact of lifestyle on gut barrier function, bacterial translocation and risk of prostate cancer, from 2020-09-01 to 2023-04-30
  • Interaction between environment, diet, physical activities, and sexual habits, in the risk of prostate cancer. Validation of biomarkers to personnalize preventive interventions., from 2012-10-01 to 2021-12-31
  • Patrons alimentaires à base de plantes et prévention du cancer de la prostate: une étude de cohorte prospective, from 2020-12-16 to 2022-12-31
Data provided by the Université Laval research projects registery